Academic literature on the topic 'Dopaminergici'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Dopaminergici.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Dopaminergici"
Colao, Annamaria, and Renata Simona Auriemma. "Iperprolattinemia, farmaci dopaminergici e valvulopatie: vero o falso?" L'Endocrinologo 13, no. 3 (June 2012): 127–31. http://dx.doi.org/10.1007/bf03345965.
Full textFrazzitta, Giuseppe. "La malattia di Parkinson: fi siopatologia, cure farmacologiche, multidisciplinarietà." PNEI REVIEW, no. 2 (November 2022): 9–19. http://dx.doi.org/10.3280/pnei2022-002002.
Full textDzoljic, Eleonora, Zorica Nesic, Radan Stojanovic, Nevena Divac, Zoran Todorovic, Sonja Vuckovic, Vladimir Kostic, and Milica Prostran. "Azotni oksid, neurodegeneracija i Parkinsonova bolest." Vojnosanitetski pregled 62, no. 10 (2005): 751–56. http://dx.doi.org/10.2298/vsp0510751d.
Full textPrysiazhniuk, A. I., M. P. Rudyk, M. Chervinska, T. V. Dovbynchuk, L. M. Skivka, and G. M. Tolstanova. "Role of peripheral dopaminergic system in the pathogenesis of experimental colitis in rats." Ukrainian Biochemical Journal 89, no. 4 (July 21, 2017): 56–67. http://dx.doi.org/10.15407/ubj89.04.056.
Full textWerner, Felix-Martin, and Rafael Coveñas. "Comparison of Mono-dopaminergic and Multi-target Pharmacotherapies in Primary Parkinson Syndrome and Assessment Tools to Evaluate Motor and Non-motor Symptoms." Current Drug Therapy 14, no. 2 (August 27, 2019): 124–34. http://dx.doi.org/10.2174/1574885513666181115104137.
Full textFernández-López, Blanca, Daniel Romaus-Sanjurjo, María Eugenia Cornide-Petronio, Sonia Gómez-Fernández, Antón Barreiro-Iglesias, and María Celina Rodicio. "Full Anatomical Recovery of the Dopaminergic System after a Complete Spinal Cord Injury in Lampreys." Neural Plasticity 2015 (2015): 1–10. http://dx.doi.org/10.1155/2015/350750.
Full textNiu, Shiba, Weibo Shi, Yingmin Li, Shanyong Yi, Yang Li, Xia Liu, Bin Cong, and Guanglong He. "Endoplasmic Reticulum Stress Is Associated with the Mesencephalic Dopaminergic Neuron Injury in Stressed Rats." Analytical Cellular Pathology 2021 (September 8, 2021): 1–9. http://dx.doi.org/10.1155/2021/7852710.
Full textBarbanti, Piero, Cinzia Aurilia, Gabriella Egeo, Luisa Fofi, Fiorella Guadagni, and Patrizia Ferroni. "Dopaminergic symptoms in migraine: A cross-sectional study on 1148 consecutive headache center-based patients." Cephalalgia 40, no. 11 (June 2, 2020): 1168–76. http://dx.doi.org/10.1177/0333102420929023.
Full textGale, Samuel D., and David J. Perkel. "Physiological Properties of Zebra Finch Ventral Tegmental Area and Substantia Nigra Pars Compacta Neurons." Journal of Neurophysiology 96, no. 5 (November 2006): 2295–306. http://dx.doi.org/10.1152/jn.01040.2005.
Full textWasel, Ola, and Jennifer L. Freeman. "Chemical and Genetic Zebrafish Models to Define Mechanisms of and Treatments for Dopaminergic Neurodegeneration." International Journal of Molecular Sciences 21, no. 17 (August 20, 2020): 5981. http://dx.doi.org/10.3390/ijms21175981.
Full textDissertations / Theses on the topic "Dopaminergici"
GAMBARDELLA, Cristina. "Caratterizzazione della corrente h in neuroni dopaminergici della substantia nigra pars compacta." Doctoral thesis, Università degli studi di Ferrara, 2011. http://hdl.handle.net/11392/2388763.
Full textGIUSTIZIERI, MICHELA. "Meccanismi di modulazione presinaptica nei neuroni dopaminergici della substantia nigra pars compacta." Doctoral thesis, Università degli Studi di Roma "Tor Vergata", 2008. http://hdl.handle.net/2108/561.
Full textPresynaptic inhibition is a mechanism of synaptic modulation normally observed in the synapses of the nervous system. This process starts upon activation of a large number of presynaptic receptors and leads to the decreased probability of vesicles to fuse to the cell membrane. One of the most common mechanism consists in the inhibition of the voltage dependent calcium channels (VDCC) located on the active zone of the presynaptic neuron. However, there is evidence for another form of presynaptic inhibition with a direct impairment of the vescicular release machinery. In my thesis I have investigated the mechanisms of presynaptic inhibition by group III metabotropic glutamate receptors (mGluRs) and GABAB receptors of the GABAergic neurotransmission to dopamine (DA) neurones of the rat substantia nigra pars compacta (SNc). The group III mGluRs agonist L-(+)-2-amino-4-phosphonobutyric acid (AP4, 100 μM) and the GABAB receptor agonist baclofen (10 μM) reversibly depressed the frequency of spontaneous inhibitory postsynaptic currents (sIPSCs) to 48.5 ± 3.7 % and 83.6 ± 2.3 % of control, respectively, with no effect in their amplitude. AP4 did not affect miniature inhibitory postsynaptic currents (mIPSCs) recorded in tetrodotoxin (TTX, 1 μM) and cadmium (100 μM), while in TTX (1 μM) and barium (1 mM), mIPSCs frequency was reduced to 75.3 ± 2.8 % of control. In contrast, baclofen reduced mIPSCs frequency either in cadmium (70.0 ± 6.7 % of control) or barium (52.3 ± 2.9 % of control). In TTX and ionomycin (2 μM), baclofen significantly reduced mIPSCs frequency to 71.8 ± 6.9 % of control, while AP4 had no effect. Similarly, in TTX and α-latrotoxin (α-LTX, 0.3 nM), the frequency of mIPSCs was reduced by baclofen to 64.5 ± 4.8 % of control, but was insensitive to AP4. Finally, in the continuous presence of baclofen, AP4 failed to produce any further reduction of sIPSCs frequency. The conclusion of this study is that group III mGluRs depress GABA release to DA neurons of the SNc through inhibition of presynaptic voltage-dependent calcium channels, while presynaptic GABAB receptors also impair transmitter exocytosis, and both mechanisms coexist on the same synapses. This characterization provides new insights about the role of these presynaptic receptors in the physiology of the substantia nigra and their potential involvement in the treatment of neurodegenerative diseases such as Parkinson’s Disease.
LALLAI, VALERIA. "L’isolamento sociale riduce marcatamente la risposta dei neuroni dopaminergici mesocorticali agli stimoli piacevoli." Doctoral thesis, Università degli Studi di Cagliari, 2015. http://hdl.handle.net/11584/266621.
Full textCUCCHIARONI, MARIA LETIZIA. "Meccanismi di vulnerabilità dei neuroni dopaminergici mesencefalici di ratto esposti a fattori neurotossici ambientali." Doctoral thesis, Università degli Studi di Roma "Tor Vergata", 2009. http://hdl.handle.net/2108/848.
Full textIt is well known that several neurodegenerative diseases, such as Parkinson disease, have a multifactorial origin (multiple hit hypothesis), which suggests that neuronal loss is a result of multiple factors. Among them, environmental factors are the most important. Although a variety of neurological processes can be adversely affected, the dopaminergic system appears to be a major target for environmental neurotoxins. The hypothesis that L-BMAA (L-β-methylamino-L-alanine), a nonprotein amino acid found in the Cycas micronesica seeds in western pacific islands, is involved in the development of amyotrophic lateral sclerosis/Parkinson-dementia complex (ALS-PDC complex) has risen and fallen since its initial proposal in 1987. In the last ten years the interest for this toxin has grown due to the discovery that it can be produced by many strains of Nostoc cyanobacterias, present throughout the world. Moreover L-BMAA can bind proteins. This bound form may function as an endogenous neurotoxic reservoir, accumulating and being released during protein catabolism. In order to analyze the effects of this amino acid, we have performed electrophysiological, pharmacological, morphological and toxicological studies on dopaminergic neurons of SNc. In these neurons puff-application of L-BMAA (3 mM, 10 psi 1.0 s) causes an inward current (mean = 454.48 34.65, n = 73) and a transient increase of intracellular calcium (R mean = 0.368 ± 0.062, n = 13). These effects are mediated by the activation of group I metabotropic glutamate receptors (mGluR1) and they are reversibly blocked by the application of the antagonist CPCCOEt (100 μM) (current: 41.56 ± 3.61 % of control, n = 24; calcium: 28.43 ± 5.96 % of control, n = 7). Bath application of CNQX (10 μM), a competitive antagonist of AMPA receptors, partially inhibits the L-BMAA-induced current (current: 93,09 ± 1,97 % of control, n = 24) but it has no effect on the calcium concentration (100.17 ± 9.93 % of control, n = 6). SOCs/TRPC channels are present in the dopaminergic cells of SNc and they mediate the intracellular calcium increase due to the activation of mGluR1. Indeed SKF 96365 (100 μM) and Ruthenium Red (20 μM), two antagonists of TRPC channels, are able to reduce the L-BMAA-induced inward current (42.125 ± 4.35 % of control, n = 8 and 27.05 ± 8.3 % of control, n = 6 respectively). Moreover SKF 96365 (100 μM) reduces the intracellular calcium increase induced by L-BMAA (43.57 ± 7.9 % of control). It is known that L-BMAA, in the presence of carbonate, has a chemical structure similar to glutamic acid, however it is not re-uptaken by EAATs, the excitatory amino acid transporters. Interestingly, in GABAergic interneurons, L-BMAA activates AMPA receptors but not mGluR1, and this activation causes inward current without any change in intracellular calcium concentration. However mGluR1 are present in these neurons because application of DHPG (30 μM), the selective agonist, produces inward currents. In order to confirm the toxic effects of this amino acid we have treated midbrain slices with L-BMAA for 12, 20 and 30 minutes and we have seen irreversible modification of cellular properties (decrease in membrane resistance, inability to evoke firing, elevated intracellular calcium). As a consequence of the treatments, cytocrome C is released in the cytoplasm, but in the presence of AMPA and mGluR1 antagonists, this effect is blocked. In conclusion this study demonstrates that L-BMAA could be considered a possible toxic agent for the dopaminergic neurons and provides new insights into the role of this amino acid in the aetiology of Parkinson disease.
ANGIONI, LAURA. "Ossitocina nella Sostanza Nera del ratto: azione sull'attività locomotoria e interazione con i neuroni dopaminergici, glutammatergici e GABAergici nigrali." Doctoral thesis, Università degli Studi di Cagliari, 2016. http://hdl.handle.net/11584/266640.
Full textESPA, ELENA. "Meccanismo d'azione del Pramipexolo nella terapia della malattia di Parkinson." Doctoral thesis, Università degli Studi di Cagliari, 2015. http://hdl.handle.net/11584/266366.
Full textCAVALLERI, LAURA. "Generazione e caratterizzazione di neuroni dopaminergici mesencefalici umani derivati da cellule staminali pluripotenti indotte da utilizzarsi come componente di dispositivi terapeutici per parkinsonismi." Doctoral thesis, Università degli studi di Modena e Reggio Emilia, 2022. http://hdl.handle.net/11380/1273446.
Full textThe degeneration of dopaminergic (DA) neurons of the ventral mesencephalon is considered one of the hallmarks in Parkinson’s disease (PD) and Parkinsonism. Their susceptibility to damage and their adaptability and plasticity were initially studied in animal models in order to understand the cellular and molecular mechanisms and the action of pharmacological therapeutics. The recent introduction of human inducible pluripotent stem cells (iPSCs) technology and the development of protocols for their differentiation into neurons with a DA phenotype has permitted the direct evaluation of cellular mechanisms of PD and Parkinsonism, the mechanism of action of anti-parkinsonian drugs and the exploratory applications of various aspects of cell therapy. The aim of this thesis was the generation and phenotypic characterization of human DA neurons amenable to be used as a tool for the development of a variety of therapeutic devices based on cell therapy, in particular implantable whole-organic electronic devices. These devices were designed to be implanted in animal models of PD for a loco-regional therapy driven by electrical and chemical stimuli to support the engraftment of DA neuron precursors, maximizing their differentiation and function. In order to achieve high quality and reproducible human DA neuron precursors that are able to differentiate and mature into functional DA neurons that respond to electrical and chemical stimuli, therefore amenable to the above described use, this work was organized in four main subprojects. The first subproject was dedicated to the optimization of the methods of differentiation of human iPSCs into mesencephalic DA neuron precursors using a previously published protocol (Fedele et al. 2017). These DA neuron precursors can be expanded for several passages and stored in liquid nitrogen for any future use. The second subproject was dedicated to the differentiation of mesencephalic DA precursors into mature DA neurons that were characterized by immunofluorescence, quantitative PCR, HPLC and electrophysiological analyses. The DA phenotype of the neurons was investigated by testing their response to two dopaminergic agonists (i.e., pramipexole and piribedil) currently used for the treatment of PD. Recent data have demonstrated a neurotrophic effect produced by an anti-parkinsonian DA D2/D3 receptor (D2R/D3R) agonist, ropinirole (Collo et al. 2018). Based on these findings, the cellular and molecular effects of pramipexole and piribedil on human DA neurons were evaluated by studying morphological changes related to structural plasticity and the activation of intracellular pathways. The neuroprotective and neuroregenerative properties of these two pharmacological agents were also studied. The third subproject was dedicated to the study of the effects of the electrical stimulation on the structural plasticity of human DA neurons. Several reports have shown that electrical stimulation can promote neuronal differentiation and neurite growth of various neuronal cell types in vitro, including PC12 (Jing et al. 2019) and human neural stem cells (Stewart et al. 2015). The fourth subproject was dedicated to the generation of human iPSCs from peripheral blood mononuclear cells (PBMCs) donated from a novel set of healthy controls and patients affected by a Parkinsonism, i.e., the multiple system atrophy (MSA). The iPSC clones obtained from the control and the patient underwent a phenotypic characterization to examine the presence of pluripotency markers by immunofluorescence and quantitative PCR analysis, karyotype analysis, pluripotency and trilineage differentiation potential. The iPSCs were subsequently differentiated into mesencephalic DA neurons and assessed for their pharmacological response to dopaminergic agonists.
SCIAMANNA, GIUSEPPE. "La disfunzione del recettore striatale D2 induce un’alterata trasmissione GABAergica in un modello murino di distonia DYT1." Doctoral thesis, Università degli Studi di Roma "Tor Vergata", 2009. http://hdl.handle.net/2108/849.
Full textDYT1 dystonia is a severe form of inherited generalized dystonia, caused by a deletion in the DYT1 gene encoding the protein torsinA. The physiological function of torsinA is unclear, though it has been proposed to perform chaperone-like functions, assist in protein trafficking, membrane fusion and participate in secretory processing. Alterations in GABAergic signaling have been involved in the pathogenesis of dystonia. I recorded GABA- and glutamate-mediated synaptic currents from striatal neurons obtained from a mouse model of DYT1 dystonia. In medium spiny neurons (MSNs) from mice expressing human mutant torsinA (hMT), we observed a significantly higher frequency, but not amplitude, of GABAergic spontaneous inhibitory postsynaptic currents (sIPSCs) and miniature currents (mIPSCs), whereas glutamatergic spontaneous excitatory synaptic potentials (sEPSCs) activity was normal. No alterations were found in mice overexpressing normal human torsinA (hWT). To identify the possible sources of the increased GABAergic tone, I recorded GABAergic Fast-Spiking (FS) interneurons that exert a feed-forward inhibition on MSNs. Both sEPSC and sIPSC recorded from hMT FS interneurons were comparable to hWT and controls.In physiological conditions, dopamine (DA) D2 receptor act presynaptically to reduce striatal GABA release. Notably, application of the D2-like receptor agonist quinpirole failed to reduce the frequency of sIPSCs in MSNs from hMT as compared to hWT and controls. Likewise, the inhibitory effect of quinpirole was lost on evoked IPSCs both in MSNs and FS interneurons from hMT mice. My findings demonstrate a disinhibition of GABAergic synaptic activity, that can be partially attributed to a D2 DA receptor dysregulation. A rise in GABA transmission would result in a profound alteration of striatal output, that might be relevant to the pathogenesis of dystonia.
Bloomfield, Michael. "Dopaminergic mechanisms underlying psychosis." Thesis, Imperial College London, 2014. http://hdl.handle.net/10044/1/44332.
Full textSzostak, Carolyn Margaret. "Dopaminergic mechanisms in conditioned circling." Thesis, University of British Columbia, 1988. http://hdl.handle.net/2429/29438.
Full textMedicine, Faculty of
Graduate
Books on the topic "Dopaminergici"
Halász, B., K. Fuxe, L. F. Agnati, M. Kalia, M. Goldstein, K. Andersson, A. Härfstrand, and B. Clark. The Dopaminergic System. Berlin, Heidelberg: Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-642-69948-1.
Full text1937-, Bodis-Wollner Ivan, Piccolino Marco, and International Brain Research Organization. Congress, eds. Dopaminergic mechanisms in vision. New York: Liss, 1988.
Find full textUmberto, Di Porzio, Pernas-Alonso Roberto, and Perrone-Capano Carla, eds. Development of dopaminergic neurons. Austin: R.G. Landes Co., 1999.
Find full textWoodruff, G. N., J. A. Poat, and P. J. Roberts, eds. Dopaminergic Systems and their Regulation. London: Palgrave Macmillan UK, 1986. http://dx.doi.org/10.1007/978-1-349-07431-0.
Full textN, Woodruff Geoffrey, Poat J. A, Roberts Peter J, and International Congress of Pharmacology (9th : 1984 : London, England), eds. Dopaminergic systems and their regulation. Weinheim, Federal Republic of Germany: VCH Verlagsgesellschaft, 1986.
Find full textN, Woodruff G., Poat J. A, Roberts P. J, and IUPHAR International Congress of Pharmacology, (9th : 1984 : London), eds. Dopaminergic systems and their regulation. Basingstoke: Macmillan, 1986.
Find full textObeso, J. A., R. Horowski, and C. D. Marsden, eds. Continuous Dopaminergic Stimulation in Parkinson’s Disease. Vienna: Springer Vienna, 1988. http://dx.doi.org/10.1007/978-3-7091-8954-2.
Full textParkinson's disease: Role of continuous dopaminergic stimulation. Crowthorne: ESP Bioscience, 2012.
Find full textBaron, J. C., D. Comar, L. Farde, J. L. Martinot, and B. Mazoyer, eds. Brain Dopaminergic Systems: Imaging with Positron Tomography. Dordrecht: Springer Netherlands, 1991. http://dx.doi.org/10.1007/978-94-011-3528-3.
Full textBeart, P. M., G. N. Woodruff, and D. M. Jackson, eds. Pharmacology and Functional Regulation of Dopaminergic Neurons. London: Palgrave Macmillan UK, 1988. http://dx.doi.org/10.1007/978-1-349-10047-7.
Full textBook chapters on the topic "Dopaminergici"
Markstein, R., J. M. Vigouret, A. Enz, D. Coward, A. Jaton, and U. Briner. "Dopaminergic Ergots." In Pharmacology and Functional Regulation of Dopaminergic Neurons, 22–28. London: Palgrave Macmillan UK, 1988. http://dx.doi.org/10.1007/978-1-349-10047-7_4.
Full textSeifert, Roland. "Dopaminergic System." In Basic Knowledge of Pharmacology, 101–10. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-18899-3_8.
Full textHalász, Béla. "Introduction to Neuroendocrinology." In The Dopaminergic System, 1–9. Berlin, Heidelberg: Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-642-69948-1_1.
Full textFuxe, Kjell, Luigi F. Agnati, Madhu Kalia, Menek Goldstein, Kurt Andersson, and Anders Härfstrand. "Dopaminergic Systems in the Brain and Pituitary." In The Dopaminergic System, 11–25. Berlin, Heidelberg: Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-642-69948-1_2.
Full textClark, Barbara J. "The Role of Dopamine in the Periphery." In The Dopaminergic System, 27–39. Berlin, Heidelberg: Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-642-69948-1_3.
Full textKuznetsov, Alexey, and Boris Gutkin. "Dopaminergic Cell Models." In Encyclopedia of Computational Neuroscience, 1034–42. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4614-6675-8_86.
Full textMcQuiston, Rory. "Mesolimbic Dopaminergic Projections." In Encyclopedia of Clinical Neuropsychology, 2151. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-57111-9_335.
Full textMcQuiston, Rory. "Mesolimbic Dopaminergic Projections." In Encyclopedia of Clinical Neuropsychology, 1. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56782-2_335-2.
Full textKuznetsov, Alexey, and Boris Gutkin. "Dopaminergic Cell Models." In Encyclopedia of Computational Neuroscience, 1–11. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4614-7320-6_86-2.
Full textMcQuiston, Rory. "Mesolimbic Dopaminergic Projections." In Encyclopedia of Clinical Neuropsychology, 1577. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-0-387-79948-3_335.
Full textConference papers on the topic "Dopaminergici"
Ordonez-Sanchez, Alejandro A., Omar Jimenez-Ramirez, Jose A. Cardenas-Valderrama, Mario Alan Quiroz-Juarez, Leonardo Palacios-Luengas, and Ruben Vazquez Medina. "Generator of Synthetic Dopaminergic Signals." In 2019 International Conference on Electronics, Communications and Computers (CONIELECOMP). IEEE, 2019. http://dx.doi.org/10.1109/conielecomp.2019.8673110.
Full textComerford, James P., Steve Perryman, Amy Pruszenski, Frank Thorn, and Richard Held. "Assessment of Lateral Interaction Across the Visual Field Using Hermann Grid Contrast Thresholds." In Vision Science and its Applications. Washington, D.C.: Optica Publishing Group, 1997. http://dx.doi.org/10.1364/vsia.1997.sae.10.
Full textJaskir, Alana, and Michael Frank. "Computational advantages of dopaminergic states for decision making." In 2019 Conference on Cognitive Computational Neuroscience. Brentwood, Tennessee, USA: Cognitive Computational Neuroscience, 2019. http://dx.doi.org/10.32470/ccn.2019.1390-0.
Full textLiu, Ching-Lung, Chien-Fu F. Chen, Kuo-Hsing Ma, and Yen-Ta Lu. "The effects of chronic intermittent hypoxia on dopaminergic neurodegeneration." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa2011.
Full textMendes, Daniele Q., and Luis Alfredo V. de Carvalho. "Creativity and Delusions: The Dopaminergic Modulation of Cortical Maps." In 5. Congresso Brasileiro de Redes Neurais. CNRN, 2016. http://dx.doi.org/10.21528/cbrn2001-072.
Full textAlavi, Azadeh, Brenton Cavanagh, Gervase Tuxworth, Adrian Meedeniya, Alan Mackay-Sim, and Michael Blumenstein. "Automated classification of dopaminergic neurons in the rodent brain." In 2009 International Joint Conference on Neural Networks (IJCNN 2009 - Atlanta). IEEE, 2009. http://dx.doi.org/10.1109/ijcnn.2009.5178740.
Full textLavrova, Alina, Mikhail Akimov, Viktor Blokhin, Natalia Gretskaya, and Vladimir Bezuglov. "NOVEL MULTIFUNCTIONAL COMPOUNDS FOR TARGETED DELIVERY TO DOPAMINERGIC NEURONS." In XVI International interdisciplinary congress "Neuroscience for Medicine and Psychology". LLC MAKS Press, 2020. http://dx.doi.org/10.29003/m1121.sudak.ns2020-16/291.
Full textGonzalez-Lopez, Adrian, Alina Aguirre-Quevedo, Ines Lopez-Alonso, Estefania Batalla-Solis, Laura Amado-Rodriguez, Antonio Fueyo, and Guillermo M. Albaiceta. "Mechanical Ventilation Triggers Hippocampal Apoptosis By Vagal And Dopaminergic Pahways." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a3068.
Full textAzuma, K., H. Takahashi, T. Kan, J. Tanimura, K. Ito, K. Matsumoto, and I. Shimoyama. "Quantitative evaluation of the influence of dopaminergic neuron on flapping locomotion." In 2013 IEEE 26th International Conference on Micro Electro Mechanical Systems (MEMS). IEEE, 2013. http://dx.doi.org/10.1109/memsys.2013.6474162.
Full textDunovan, Kyle, Catalina Vich, Matthew Clapp, Jonathan Rubin, and Timothy Verstynen. "Dopaminergic changes in striatal pathway competition modify specific cognitive decision parameters." In 2018 Conference on Cognitive Computational Neuroscience. Brentwood, Tennessee, USA: Cognitive Computational Neuroscience, 2018. http://dx.doi.org/10.32470/ccn.2018.1034-0.
Full textReports on the topic "Dopaminergici"
Przedborski, Serge. Role of Inflammation in MPTP-Induced Dopaminergic Degeneration. Fort Belvoir, VA: Defense Technical Information Center, December 2005. http://dx.doi.org/10.21236/ada446427.
Full textPrzedborski, Serge, and Vernice Jackson-Lewis. Interaction of Synuclein and Inflammation in Dopaminergic Neurodegeneration. Fort Belvoir, VA: Defense Technical Information Center, June 2014. http://dx.doi.org/10.21236/ada606023.
Full textPrzedborski, Serge. Interaction of Synuclein and Inflammation in Dopaminergic Neurodegeneration. Fort Belvoir, VA: Defense Technical Information Center, July 2009. http://dx.doi.org/10.21236/ada506349.
Full textPrzedborski, Serge. Interaction of Synuclein and Inflammation in Dopaminergic Neurodegeneration. Fort Belvoir, VA: Defense Technical Information Center, July 2010. http://dx.doi.org/10.21236/ada564265.
Full textPrzedborski, Serge, and Vernice Jackson-Lewis. Interaction of Synuclein and Inflammation in Dopaminergic Neurodegeneration. Fort Belvoir, VA: Defense Technical Information Center, July 2012. http://dx.doi.org/10.21236/ada564270.
Full textPrzedborski, Serge. Role of Inflammation in MPTP-Induced Dopaminergic Neuronal Death. Fort Belvoir, VA: Defense Technical Information Center, December 2008. http://dx.doi.org/10.21236/ada494929.
Full textPrzedborski, Serge E. Role of Nitric Oxide in MPTP Induced Dopaminergic Neuron. Fort Belvoir, VA: Defense Technical Information Center, September 2000. http://dx.doi.org/10.21236/ada384796.
Full textPrzedborski, Serge E. Role of Nitric Oxide in MPTP-Induced Dopaminergic Neuron Degeneration. Fort Belvoir, VA: Defense Technical Information Center, September 2004. http://dx.doi.org/10.21236/ada450371.
Full textGarris, Paul A., Tim Schallert, and Byron A. Heidenreich. Phasic Dopaminergic Signaling and the Presymptomatic Phase of Parkinson's Disease. Fort Belvoir, VA: Defense Technical Information Center, July 2004. http://dx.doi.org/10.21236/ada430314.
Full textPrzedborski, Serge. Role of Nitric Oxide in MPTP-Induced Dopaminergic Neuron Degeneration. Fort Belvoir, VA: Defense Technical Information Center, September 2002. http://dx.doi.org/10.21236/ada416386.
Full text